SCHEMBL3528056

SCHEMBL3528056

CONS(=O)(=O)c1cc(C(=O)O)c(F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 9/20 0.46
KDM4E B2RXH2 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
FABP5 Q01469 6/20 0.37
PTK2B Q14289 1/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
BCL2L1 Q07817 1/20 0.34
MCL1 Q07820 1/20 0.34
ACLY P53396 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527672 0.87 ATM (0.47) KDM4ENPSR1PTK2BATMALDH1A1
SCHEMBL13542939 0.85 FABP4 (0.34) FABP4KDM4ENPSR1SLC1A3SLC1A2
SCHEMBL13545076 0.84 HMGCR (0.36) FABP4KDM4ENPSR1SLC1A3SLC1A2
SCHEMBL3528018 0.82 FABP4 (0.43) FABP4KDM4ENPSR1SLC1A3SLC1A2
SCHEMBL3526814 0.79 NPSR1 (0.56) FABP4KDM4ENPSR1SLC1A3SLC1A2
SCHEMBL3528359 0.79 FABP4 (0.41) FABP4KDM4ENPSR1SLC1A3SLC1A2
SCHEMBL2540297 0.78 CA12 (0.47) FABP4KDM4ESLC1A3SLC1A2SLC1A1
SCHEMBL3530828 0.77 KMT2A (0.45) NPSR1
SCHEMBL3528445 0.76 CA12 (0.58) FABP4SLC1A3SLC1A2SLC1A1ATM
SCHEMBL13542933 0.76 POLB (0.41) ATMALDH1A1ACLYCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 FABP4 4325/4885KDM4E 4644/4885NPSR1 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.